BioSig Announces Completion of PURE EPa?? System Installation at New Medical Center

Westport, CT, Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (a??BioSiga?? or the a??Companya??), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its PURE EPa?? System and started conducting patient cases at Deborah Heart and Lung Center in Browns Mills, New Jersey.PURE EPa?? System evaluation and clinical data collection is being conducted under the leadership of Raffaele Corbisiero, M.D.a??We are pleased to commence our clinical operations at Deborah Heart and Lung Center. As an innovative and rapidly growing company, we are excited to have physicians at Deborah not only utilize our technology, but also contribute to its advancement. Given COVID-19a??s detrimental effects on cardiovascular health, this relationship cannot come at a more important time,a?? commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. a??Intracardiac signals are the foundation of everything we do in EP, but we can't treat what we don't see. I am impressed by our early experience with PURE EPa?? showing more of the cardiac signals we want to see,a?? commented Raffaele Corbisiero, M.D., Deborah Heart and Lung Center.BioSig is currently conducting patient cases under the clinical trial titled a??Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)a?? at Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas and Mayo Clinic Florida Campus in Jacksonville, Florida. The Company recently added Massachusets General Hospital and the Hospital of the University of Pennsylvania to its clinical sites.A 
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Май 2021    »